Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma With the Anti-Pd-1, Tislelizumab: Results of a Phase 2, Single-Arm, Multicenter Study
Leukemia - United Kingdom
doi 10.1038/s41375-019-0545-2
Full Text
Open PDFAbstract
Available in full text
Date
September 13, 2019
Authors
Publisher
Springer Science and Business Media LLC